In:
Neurology: Clinical Practice, Ovid Technologies (Wolters Kluwer Health), Vol. 12, No. 2 ( 2022-04), p. 131-138
Abstract:
Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial. Methods The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E. Results We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality). Discussion These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials. Trial Registration Information 2CARE and CREST are registered at clinicaltrials.gov . 2CARE NCT00608881 , registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426 , registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.
Type of Medium:
Online Resource
ISSN:
2163-0402
,
2163-0933
DOI:
10.1212/CPJ.0000000000001161
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
2645818-4
Bookmarklink